COMMUNIQUÉS West-GlobeNewswire

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
20/03/2026
Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 (GLOBE NEWSWIRE) -- Prodrug of oral amyloid beta aggregation modulator demonstrated improved absorption characteristics, leading to substantially [...]
On Match Day, ApolloMD Opens Applications for $5,000 Emergency Medicine Scholarship
20/03/2026
ATLANTA , March 20, 2026 (GLOBE NEWSWIRE) -- As medical students across the country learn where they will train during Match Day, ApolloMD is opening applications for its 2026 Emergency Medicine Scholarship . The annual [...]
The Cost of Bleeding Revealed: Menstruation costs £20,359 a lifetime, sparking calls for Government action
20/03/2026
New consumer research reveals women and people with cycles spend an average of £20,359 on menstruating in their lifetime More than 1 in 3 (37%) of respondents struggle to afford period products 39% cut back on other [...]
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
20/03/2026
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, currently in a Phase 1/2 [...]
Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis
20/03/2026
Louvain ‑ la ‑ Neuve, Belgique, le 20 mars 2026 — IBA (Ion Beam Applications S.A., EURONEXT) , leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de production de [...]
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
20/03/2026
Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, [...]
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
20/03/2026
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
Pacific Health Care Organization, Inc. Reports its 2025 Year-End Financial Results
19/03/2026
Irvine, CA, March 19, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed Tuesday with the Securities and Exchange Commission (the “SEC”) its annual report on Form 10-K [...]
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
20/03/2026
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant [...]
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
19/03/2026
MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key [...]
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
19/03/2026
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – -- [...]
Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités
20/03/2026
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2. Population cible de phase 2 : [...]
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
19/03/2026
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension [...]
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
19/03/2026
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 in Newly [...]
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and [...]
Solésence To Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 31, 2026
19/03/2026
ROMEOVILLE, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
19/03/2026
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
19/03/2026
RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year [...]
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
19/03/2026
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]

Pages